Public health and economic impact of COVID-19 vaccination with the Pfizer-BioNTech COVID-19 Vaccine, KP.2, among adults in 2024/2025 in the United States
Vaccination with the Pfizer BioNTech COVID-19 vaccine, KP.2, is a cost-effective measure from the societal perspective at a willingness-to-pay threshold of $50,000 that could reduce the health and economic burden of COVID-19.
Authors
- Abby E. Rudolph (ORCID: https://orcid.org/0000-0003-1786-3307)
- Santiago M. C. Lopez (ORCID: https://orcid.org/0000-0001-7714-1707)
- Elizabeth Thoburn
- Manuela Di Fusco (ORCID: https://orcid.org/0000-0003-0079-7331)
- Benjamin Yarnoff (ORCID: https://orcid.org/0000-0002-5147-1588)
- Alon Yehoshua (ORCID: https://orcid.org/0009-0009-2920-916X)
- Kinga Marczell
Institutions
- Ithaka Harbors (US)
- Pfizer (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1080/13696998.2024.2429335
- Citations
- 5
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.95
Funders
- Pfizer